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We conducted a case–control study in a Japanese population to investigate the association between dietary isoflavone intake and the
risk of colorectal adenoma. Participants who underwent magnifying colonoscopy with dye spreading as part of a cancer screening
programme responded to a self-administered questionnaire, which included lifestyle information and intake of 145 food items, before
the colonoscopy. A total of 721 case and 697 control subjects were enrolled. Odds ratios (ORs) and 95% confidence intervals (CIs)
were estimated using unconditional logistic regression models. We found a significant inverse association between dietary isoflavone
intake and the risk of colorectal adenoma in men and women combined. However, the inverse association was not linear; rather, all
quartiles above the first showed a similar decrease in risk, with multivariable-adjusted ORs and 95% CIs compared with the lowest
quartile of 0.77 (0.57–1.04), 0.76 (0.56–1.02) and 0.70 (0.51–0.96) in the second, third and highest quartiles, respectively (P for
trend¼0.03). Of interest, the observed association was more prominent in women than in men. The observed ceiling effect
associated with higher isoflavone intake suggests that a lower intake of dietary isoflavone might be associated with an increased risk of
colorectal adenoma in Japanese populations.
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The incidence of colorectal cancer, a common malignancy in
developed countries, is higher in men than in women (Parkin et al,
2002), a difference which has been related to sex hormones, in
particular oestrogen. Although the function of oestrogen in the
aetiology of colorectal cancer has not been established, an
association is supported by several studies (MacLennan et al,
1995; He ´bert-Croteau, 1998; Grodstein et al, 1999; Chlebowski
et al, 2004; Linsalata et al, 2005).
Isoflavones such as genistein and daidzein are classified as
phyto-oestrogens. Dietary phyto-oestrogens are plant-derived,
non-steroidal compounds with weak oestrogen-like activity,
occurring predominantly in soya beans and soya products.
A better understanding of the association between dietary soya foods
or isoflavone intake and colorectal cancer risk would be useful.
To date, seven studies have investigated the association between
soya product consumption and the risk of colorectal cancer or
adenoma (Hoshiyama et al, 1993; Witte et al, 1996; Marchand et al,
1997; Ho et al, 2006; Wakai et al, 2006; Oba et al, 2007; Akhter
et al, 2008), of which five reported an inverse association. In
contrast, only three studies have assessed the association of
isoflavone intake with colorectal cancer risk (Cotterchio et al,
2006; Oba et al, 2007; Akhter et al, 2008), and we are unaware of
any study of colorectal adenoma.
We have investigated the possible association between dietary
isoflavone intake and the risk of colorectal adenoma, in a
case–control study in a Japanese population, who were likely to
consume relatively large amounts of isoflavones with substantial
variation.
MATERIALS AND METHODS
The Colorectal Adenoma Study in Tokyo (CAST) consisted of
examinees who underwent magnifying colonoscopy with dye
spreading as a part of a cancer screening programme provided
by the Research Center for Cancer Prevention and Screening,
National Cancer Center, between February 2004 and February
2005. Details of this programme have been provided elsewhere
(Otani et al, 2006; Yamaji et al, 2009). Eligible examinees were men
aged 50–79 years or women aged 40–79 years who underwent
total colonoscopy from the anus to the caecum. Those with a
history of any of the following diseases and conditions were
considered ineligible: colorectal adenoma, malignant neoplasm,
ulcerative colitis, Crohn’s disease, familial adenomatous polyposis,
carcinoid tumour or colectomy. All subjects gave written informed
consent, and the study protocol was approved by the institutional
review board of the National Cancer Center, Tokyo, Japan.
Among a consecutive series of 3212 examinees, 2234 met the
eligibility criteria above. According to pit-pattern classification
(Sano et al, 2005), 526 men and 256 women were determined to
have at least one adenoma. Of the remaining 1452 examinees, 482
men and 721 women were also free from other benign lesions (e.g.
hyperplastic polyps, inflammatory polyps and diverticulum) and
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ywere identified as potential controls. The potential control of 256
women was frequency matched to the female case in five age
categories (40–49, 50–54, 55–59, 60–64 and X65 years old) and
screening periods (first and second half). Because there were fewer
potential male controls than male cases, all men of the potential
controls were included in the study. Finally, the CAST consisted of
782 cases and 738 controls.
We conducted a self-administered questionnaire survey among
participants before their screening examination. The questionnaire
assessed demographic characteristics, personal and family medical
history, use of drugs and supplements, anthropometric measure-
ments, physical activity, history of smoking and alcohol drinking,
reproductive factors (women only) and other lifestyle-related factors.
The self-administered questionnaire included a food frequency
questionnaire (FFQ) that asked about 145 food and beverage items
in terms of standard portion sizes and 9 frequency categories. The
standard portion sizes of respective food items were specified in
the FFQ and the amounts were determined into three categories of
less than half, the same as, and more than 1.5 times the reference
portion size. The frequency response choices for food items were
less than once per month, 1–3 times per month, 1–2 times per
week, 3–4 times per week, 5–6 times per week, once per day, 2–3
times per day, 4–6 times per day and X7 times per day. Soya food
items included miso (fermented soya bean paste) soup, tofu (soya
bean curd) in miso soup, tofu (boiled or cold) in other dishes,
atsuage (fried tofu), koyadofu (freeze-dried tofu), aburaage (deep-
fried tofu), natto (fermented soya bean) and tonyu (soya milk
made from soya bean as major ingredient). The frequency of miso
soup consumption was divided into six categories of almost never,
1–3 days per month, 1–2 days per week, 3–4 days per week, 5–6
days per week and daily. Portion size was specified with one bowl
of miso soup equalling 150ml into the nine categories of o1 bowl
per day, 1 bowl per day, 2 bowls per day, 3 bowls per day, 4 bowls
per day, 5 bowls per day, 6 bowls per day, 7–9 bowls per day and
X10 bowls per day. Daily intake of genistein and daidzein was
calculated using values in a specially developed food composition
table for isoflavone in Japanese foods (Kimira et al, 1998; Arai
et al, 2000). This FFQ was modified from an FFQ used in a
previous population-based prospective study that had additional
food items, the validity and reproducibility of which were
evaluated previously (Tsubono et al, 1996; Tsugane et al, 2003).
Validity was assessed among subsamples of that prospective study
using 14- or 28-day dietary records. Spearman’s correlation
coefficients between the energy-adjusted intake of isoflavone from
the questionnaire and dietary records were 0.60 (daidzein) and
0.59 (genistein). Moreover, Spearman’s correlation coefficients for
daidzein and genistein between energy-adjusted intake from the
FFQ and those from serum concentrations were 0.26 and 0.22,
respectively, and with those from creatinine-adjusted urinary
excretion were 0.40 and 0.30, respectively (Yamamoto et al, 2001).
Statistical analysis
After the exclusion of 102 subjects who reported extreme total
energy intake (upper and lower 2.5%) or submitted incomplete
answers regarding dietary isoflavone intake and other confounding
variables, 721 cases (492 men and 229 women) and 697 controls
(460 men and 237 women) were entered into the analysis. Because
dietary genistein and daidzein intakes were highly correlated
(Spearman r¼0.99), the sum of genistein and daidzein is provided
here as representative for total isoflavones. Isoflavone intake was
then adjusted for total energy intake using the residual method in
the statistical model after log transformation (Kipnis et al, 1993;
Brown et al, 1994; Willett et al, 1997). Participants were divided
into quartiles of isoflavone intake based on the distribution of all
control men and women. An unconditional logistic regression
model was used to calculate odds ratios (ORs) and 95% confidence
intervals (95% CIs) of colorectal adenoma for isoflavone intake
using the lowest quartile of intake as the referent category. In
addition, ORs and 95% CIs were calculated in subgroups stratified
by adenoma site (proximal colon, distal colon and rectum), size
(o5 and X5mm) and number (1 and 41). The first statistical
model was adjusted for age, sex and screening period, whereas the
second model was further adjusted for family history of colorectal
cancer (yes or no), cigarette smoking (never, ever o20, ever
21–40, ever 440 pack-years), alcohol drinking (never, ever o150,
ever 150–299, ever X300g per week ethanol), body mass index
(o21, 21–22, 23–24, X25kgm
 2), physical activity (quartiles
based on controls), supplement use (yes or no), non-steroidal anti-
inflammatory drug use (yes or no). Age at menarche (o12, 12–13,
X14 years), menopausal status (pre or post) and current use of
female hormones (user or non-user) were also adjusted in women.
Statistical significance of the interaction terms was evaluated by
the likelihood ratio test. Tests for linear trend were estimated using
the median value of isoflavone intake and treating this variable as
continuous. All statistical tests were two tailed, and P-values o0.05
were considered statistically significant. All analyses were per-
formed using Stata Statistics/Data Analysis Special Edition version
9.2 (2007; StataCorp LP, College Station, TX, USA).
RESULTS
The demographic characteristics and lifestyle factors according to
case–control and sex had mentioned previously (Otani et al, 2006;
Yamaji et al, 2009). Table 1 shows these factors of controls
according to quartile categories of isoflavone intake. Median
(interquartile range) isoflavone intake (mg per day) among the
control group was 39.73 (24.77–62.41). The proportion of women
and supplement users, and mean intake of total isoflavone were
higher in the highest quartile group than in the other groups. In
contrast, the proportion of those using non-steroidal anti-
inflammatory drugs, ever smokers and mean alcohol consumption
was higher in the lowest quartile group. Mean body mass index,
total energy intake and age at menarche did not differ among the
highest to lowest quartiles of isoflavone consumption.
Table 2 shows the age, sex and screening-period-adjusted and
multivariable-adjusted ORs and 95% CIs of colorectal adenoma for
quartile categories of dietary isoflavone intake. Dietary isoflavone
intake was associated with a reduced risk of colorectal adenoma in
men and women combined. This inverse association was not linear;
however, rather, a similar decrease was seen across all quartiles
other than the first, with multivariable-adjusted ORs and 95%
CIs in the second, third and highest compared with the lowest
quartile of 0.77 (0.57–1.04), 0.76 (0.56–1.02) and 0.70 (0.51–0.96),
respectively (P for trend¼0.03). Stratified analysis by sex showed a
significant inverse association between isoflavone consumption and
colorectal adenoma in women, and a non-significant inverse
association in men. The multivariable-adjusted ORs (95% CIs) for
women in increasing quartile intake categories were 0.53 (0.28–
0.98), 0.44 (0.24–0.80) and 0.49 (0.27–0.90), respectively (P for
trend¼0.03).
We repeated the above analyses after excluding those who had
changed their dietary habits in the past 5 years (n¼393 subjects),
primarily on the basis that the change might have been related to
the presence of adenoma. Results were essentially the same as
those above (data not shown). We also investigated the association
between colorectal adenoma for quartile categories of dietary
isoflavone intake after further adjustment of fibre, folate, calcium
and vitamin D in the multivariate model and similar decreased
risk of association was observed (data not shown). We further
categorised the subjects into octiles. As in the quartile analysis,
however, the inverse association was not linear in the octile
groups; rather, the third to highest octiles showed a decrease in
risk, with the pattern more apparent in women, in whom multi-
variable-adjusted ORs (95% CIs) in increasing octile categories
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yTable 1 Demographic characteristics and lifestyle factors in men and women controls (n¼697)
Quartiles of energy-adjusted intake of total isoflavones (mg per day)
Lowest Second Third Highest
(o24.77) (24.77 to o39.73) (39.73 to o62.41) (X62.41)
(n¼174) (n¼175) (n¼174) (n¼174) P-value
a
Sex
Men, n (%) 141 (81.0) 120 (68.6) 105 (60.3) 94 (54.0) o0.01
Women, n (%) 33 (19.0) 55 (31.4) 69 (39.7) 80 (46.0)
Age, mean (years) 59.2 (5.6) 59.1 (6.5) 60.7 (5.6) 60.4 (5.9) 0.02
Supplement use, yes (%) 71 (40.8) 72 (41.1) 89 (51.2) 91 (52.3) 0.04
Family history of colorectal cancer, n (%) 21 (12.1) 21 (12.0) 29 (16.7) 15 (8.6) 0.15
Non-steroidal anti-inflammatory drug use, n (%) 19 (10.9) 8 (4.6) 8 (4.6) 17 (9.8) 0.04
Ever smoker, n (%) 105 (60.3) 92 (52.6) 74 (42.5) 67 (38.5) o0.01
Mean cigarettes (pack-years) 31.0 (27.8) 26.4 (24.5) 27.2 (21.6) 22.4 (21.0) 0.16
Ever drinker, n (%) 138 (79.3) 133 (76.0) 127 (73.0) 128 (73.6) 0.51
Mean alcohol (g per week ethanol) 218.4 (226.2) 201.0 (197.3) 158.1 (177.9) 140.0 (156.8) o0.01
Body mass index, mean (kgm
 2) 23.1 (2.6) 22.8 (3.0) 23.1 (2.7) 23.1 (3.0) 0.79
Physical activity, mean (MET h per day) 35.7 (6.8) 35.6 (7.0) 36.7 (7.1) 37.6 (9.2) 0.06
Total energy intake, mean (kcal per day) 1774.4 1900.0 1906.2 1839.1 0.11
Total isoflavone intake, mean (mg per day)
b 17.3 31.4 49.4 78.5 o0.01
Age at menarche, mean (years) 13.4 (1.7) 13.1 (1.2) 13.2 (1.5) 13.3 (1.4) 0.72
Postmenopausal status, n (%) 31 (93.9) 47 (85.5) 64 (92.8) 70 (87.5) 0.43
Postmenopausal hormone use, n (%) 3 (9.1) 10 (18.2) 8 (11.6) 8 (10.0) 0.47
Mean values with standard deviations (s.d.’s) in parentheses for continuous variables; number of subjects with percentages in parentheses for categorical variables.
aP-values from
analysis of variance (ANOVA) test for continuous variables; w
2-test for categorical variables.
bEnergy adjusted.
Table 2 Logistic regression models of the effect of energy-adjusted intake of total isoflavones on colorectal adenoma
Quartiles of energy-adjusted intake of total isoflavones (mg per day)
Lowest Second Third Highest
(o24.77) (24.77 to o39.73) (39.73 to o62.41) (X62.41) P-value for trend
Men and women
Controls 174 175 174 174
Cases 226 172 168 155
OR (95% CI)
a 1.00 (Reference) 0.75 (0.56–1.00) 0.73 (0.54–0.98) 0.67 (0.50–0.90) o0.01
OR (95% CI)
b 1.00 (Reference) 0.77 (0.57–1.04) 0.76 (0.56–1.02) 0.70 (0.51–0.96) 0.03
Men
Controls 141 120 105 94
Cases 173 119 114 86
OR (95% CI)
c 1.00 (Reference) 0.78 (0.55–1.10) 0.84 (0.59–1.20) 0.70 (0.49–1.02) 0.09
OR (95% CI)
d 1.00 (Reference) 0.80 (0.56–1.14) 0.89 (0.62–1.28) 0.74 (0.50–1.09) 0.18
Women
Controls 33 55 69 80
Cases 53 53 54 69
OR (95% CI)
e 1.00 (Reference) 0.59 (0.33–1.05) 0.44 (0.25–0.75) 0.56 (0.33–0.96) 0.03
OR (95% CI)
f 1.00 (Reference) 0.53 (0.28–0.98) 0.44 (0.24–0.80) 0.49 (0.27–0.90) 0.03
aAdjusted for age (40–49, 50–54, 55–59, 60–64, X65 years), sex and screening period (first or second).
bAdjusted for age (40–49, 50–54, 55–59, 60–64, X65 years), sex,
screening period (first or second), family history of colorectal cancer (yes or no), cigarette smoking (never, ever p20, ever 21–40, ever 440 pack-years), alcohol consumption
(never, ever o150, ever 150–299, ever X300g per week ethanol), body mass index (o21, 21–22, 23–24, X25kgm
 2), physical activity (o31.50, 31.50 to o34.55, X34.55
MET h per day based on controls), supplement use (yes or no) and non-steroidal anti-inflammatory drug use (yes or no).
cAdjusted for age (50–54, 55–59, 60–64, X65 years)
and screening period (first or second).
dAdjusted for age (50–54, 55–59, 60–64, X65 years), screening period (first or second), family history of colorectal cancer (yes or no),
cigarette smoking (never, ever p20, ever 21–40, ever 440 pack-years), alcohol consumption (never, ever o150, ever 150–299, ever X300g per week ethanol), body mass
index (o21, 21–22, 23–24, X25kgm
 2), physical activity (o31.50, 31.50 to o34.55, X34.55 MET h per day based on controls), supplement use (yes or no) and non-
steroidal anti-inflammatory drug use (yes or no).
eAdjusted for age (40–49, 50–54, 55–59, 60–64, X65 years) and screening period (first or second).
fAdjusted for age
(40–49, 50–54, 55–59, 60–64, X65 years), screening period (first or second), family history of colorectal cancer (yes or no), cigarette smoking (never, ever p20, ever 21–40,
ever 440 pack-years), alcohol consumption (never, ever o150, ever 150–299, ever X300g per week ethanol), body mass index (o21, 21–22, 23–24, X25kgm
 2), physical
activity (o31.50, 31.50 to o34.55, X34.55 MET h per day based on controls), supplement use (yes or no), non-steroidal anti-inflammatory drug use (yes or no), age at
menarche (o12, 12–13, X14 years), menopausal status (pre or post) and current use of female hormones (user or non-user).
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ywere 0.67 (0.26–1.70), 0.41 (0.16–1.06), 0.44 (0.18–1.05), 0.40
(0.17–0.97), 0.30 (0.13–0.72), 0.40 (0.17–0.93) and 0.42 (0.18–
0.97), respectively (P for trend¼0.03).
Stratified analysis according to site, size and number of colorectal
adenomas showed no difference in the association with isoflavone
intake by adenoma characteristics in overall men and women
(Table 3). We further tested for effect modification between isoflavone
intake and other covariates (age, sex, cigarette smoking, alcohol
drinking and body mass index) in colorectal adenoma through the
addition of multiplicative interaction terms into the model, but found
no statistically significant P-value for interaction (data not shown).
DISCUSSION
In this colonoscopy-based case–control study, we found a
significant inverse association between dietary isoflavone intake
and colorectal adenoma risk in a Japanese population. The inverse
association was not linear; with a ceiling effect observed with
higher intake, which implied conversely that a lower intake of
dietary isoflavone was related to an increased risk.
To our knowledge, this is the first study of this subject. Because
adenomas are much more common than cancers, we may have
greater power to detect the isoflavone–adenoma association.
To date, three studies have examined the association between
dietary isoflavone intake and the risk of colon (Oba et al, 2007) or
colorectal cancer (Cotterchio et al, 2006; Akhter et al, 2008), two in
Japanese (Oba et al, 2007; Akhter et al, 2008) and one in a
Caucasian population (Cotterchio et al, 2006). Although the former
two showed no clear association, the latter demonstrated a linear
inverse association between dietary isoflavone intake and color-
ectal cancer risk. Of importance, the Caucasian population
consumed a relatively low level of isoflavones, with a cut-off point
for the highest tertile of 1.097 vs 17.22mg per day for the lowest
octile in our study population; it therefore investigated the effect of
lower intake levels, which we could not observe in detail in our
study, and supported our finding that a lower intake of dietary
isoflavone was related to an increase in risk.
Isoflavones may help prevent the development of colorectal
neoplasm through their oestrogenic effect. In fact, several in vitro
and in vivo experimental studies have suggested that phyto-
oestrogens protect against colorectal cancer (Spector et al, 2003).
Phyto-oestrogens distinctly interact with oestrogen receptors (ERs)
in the normal human colon. Of the ER-a and ER-b oestrogen
receptors, phyto-oestrogens bind with high affinity to ER-b, and
consistently mediate signals to inhibit abnormal cellular prolifera-
tion in colon tumour cell lines by blocking tyrosine protein
kinases, aromatase and DNA topoisomerases. Phyto-oestrogens
also possess antioxidant activity, and inhibit cell-cycle progression
and angiogenesis in endothelial cells (Lechner et al, 2005).
We found a stronger inverse association in women than in men,
although effect modification by sex was not statistically significant.
Nonetheless, this suggested difference by sex is of particular
interest, because isoflavones may have a more important function
in the prevention of colorectal adenoma in women than in men. Of
the five of seven epidemiological studies of the association between
soya product intake and colorectal neoplasm, which provided
results for men and women separately (Marchand et al, 1997; Ho
et al, 2006; Wakai et al, 2006; Oba et al, 2007; Akhter et al, 2008),
three reported that the inverse association was more prominent
among women (Marchand et al, 1997; Ho et al, 2006; Oba et al,
2007), whereas none reported that it was stronger among men. This
sex difference in the effect of plant-derived oestrogen (isoflavones)
on colorectal neoplasm warrants further investigation.
Our study has several methodological advantages over previous
studies. First, we used a validated FFQ and calculated isoflavone intake
from a variety of dietary soya sources. Many different foods contribute
to isoflavone intake, and no single soya food category predominates.
M o r e o v e r ,o u rs u b j e c t sh a dr e l a t i v e l yl a r g ei s o f l a v o n ei n t a k ew i t h
substantial variation, making them suitable for the investigation of
this association. Second, subjects answered the questionnaire before
diagnosis, likely minimising the possibility of recall bias.
Table 3 Logistic regression models of the effect of energy-adjusted intake of total isoflavones on site, size and number of colorectal adenoma in men and
women
Quartiles of energy-adjusted intake of total isoflavones (mg per day)
Lowest Second Third Highest
(o24.77) (24.77 to o39.73) (39.73 to o62.41) (X62.41) P-value for trend
Controls 174 175 174 174
Site of adenoma
Proximal colon 114 90 94 83
OR (95% CI)
a 1.00 (Reference) 0.75 (0.52–1.08) 0.77 (0.54–1.11) 0.69 (0.47–1.00) 0.07
Distal colon 82 67 59 52
OR (95% CI)
a 1.00 (Reference) 0.87 (0.58–1.30) 0.77 (0.51–1.17) 0.71 (0.46–1.09) 0.10
Rectum 30 15 15 20
OR (95% CI)
a 1.00 (Reference) 0.47 (0.24–0.93) 0.47 (0.24–0.93) 0.68 (0.36–1.31) 0.18
Size of adenoma
o5mm 125 93 97 87
OR (95% CI)
a 1.00 (Reference) 0.77 (0.54–1.09) 0.79 (0.55–1.12) 0.70 (0.48–1.00) 0.07
X5mm 101 79 70 69
OR (95% CI)
a 1.00 (Reference) 0.74 (0.51–1.08) 0.67 (0.45–0.98) 0.73 (0.49–1.08) 0.08
Number of adenomas
1 Adenoma 132 85 101 94
OR (95% CI)
a 1.00 (Reference) 0.64 (0.45–0.91) 0.73 (0.52–1.03) 0.67 (0.47–0.95) 0.05
41 Adenomas 94 87 67 61
OR (95% CI)
a 1.00 (Reference) 0.96 (0.65–1.41) 0.72 (0.48–1.08) 0.74 (0.49–1.12) 0.07
aAdjusted for age (40–49, 50–54, 55–59, 60–64, X65 years), sex, screening period (first or second), family history of colorectal cancer (yes or no), cigarette smoking (never,
ever p20, ever 21–40, ever 440 pack-years), alcohol consumption (never, ever o150, ever 150–299, ever X300g per week ethanol), body mass index (o21, 21–22,
23–24, X25kg/m
2), physical activity (o31.50, 31.50 to o34.55, X34.55 MET h per day based on controls), supplement use (yes or no) and non-steroidal anti-inflammatory
drug use (yes or no).
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ySeveral limitations also warrant mention. First, although all
examinees underwent total colonoscopy, colorectal adenoma cases
were diagnosed according to pit-pattern classification and were
not confirmed histologically. Given an overall accuracy of pit-
pattern diagnosis of approximately 90% vs data from our institute
showing 95% accuracy, our analysis may have included a few false-
positive cases (Sano et al, 2005). Magnifying chromoendoscopy is
nevertheless a feasible and efficient method of determining
neoplastic lesions such as adenoma and the validity of its inter-
and intraobserver consistency has been confirmed (Haenszel et al,
1973; Fu et al, 2004). Second, the presence of adenoma might have
been associated with changes in dietary habits; however, the
sensitivity analysis revealed that such reverse association was less
likely. Finally, isoflavone intake and other variables were based
on self-administered questionnaires; some misclassifications of
subjects were inevitable.
In summary, we found an inverse association between dietary
isoflavone intake and the risk of colorectal adenoma in a Japanese
population, which was not linear, but rather showed a ceiling effect
associated with higher isoflavone intake; it was more prominent in
women than in men, possibly reflecting an oestrogenic effect.
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